RU2084223C1 - Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты - Google Patents

Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты Download PDF

Info

Publication number
RU2084223C1
RU2084223C1 RU9092016445A RU92016445A RU2084223C1 RU 2084223 C1 RU2084223 C1 RU 2084223C1 RU 9092016445 A RU9092016445 A RU 9092016445A RU 92016445 A RU92016445 A RU 92016445A RU 2084223 C1 RU2084223 C1 RU 2084223C1
Authority
RU
Russia
Prior art keywords
halogen
alkyl
bromine
chlorine
fluorine
Prior art date
Application number
RU9092016445A
Other languages
English (en)
Russian (ru)
Other versions
RU92016445A (ru
Inventor
Р.Бартлетт Роберт
Кэммерер Фридрих-Иоханнес
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU92016445A publication Critical patent/RU92016445A/ru
Application granted granted Critical
Publication of RU2084223C1 publication Critical patent/RU2084223C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Air Conditioning Control Device (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Indole Compounds (AREA)
RU9092016445A 1990-05-18 1990-10-24 Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты RU2084223C1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE4016178 1990-05-18
DEP4016178.1 1990-05-18
DEP4017020.9 1990-05-26
DE4017020 1990-05-26
DEP4017043.8 1990-05-26
DE4017043 1990-05-26
PCT/EP1990/001800 WO1991017748A1 (de) 1990-05-18 1990-10-24 Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU94033835A Division RU2142937C1 (ru) 1990-05-18 1990-10-24 Амиды органических кислот, способ их получения и фармацевтическая композиция

Publications (2)

Publication Number Publication Date
RU92016445A RU92016445A (ru) 1996-11-10
RU2084223C1 true RU2084223C1 (ru) 1997-07-20

Family

ID=27201216

Family Applications (2)

Application Number Title Priority Date Filing Date
RU94033835A RU2142937C1 (ru) 1990-05-18 1990-10-24 Амиды органических кислот, способ их получения и фармацевтическая композиция
RU9092016445A RU2084223C1 (ru) 1990-05-18 1990-10-24 Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU94033835A RU2142937C1 (ru) 1990-05-18 1990-10-24 Амиды органических кислот, способ их получения и фармацевтическая композиция

Country Status (28)

Country Link
US (2) US5494911A (enExample)
EP (1) EP0527736B1 (enExample)
JP (3) JP2995086B2 (enExample)
KR (1) KR100188801B1 (enExample)
CN (1) CN1051074C (enExample)
AT (1) ATE151633T1 (enExample)
AU (2) AU649421B2 (enExample)
BR (1) BR9008022A (enExample)
CA (1) CA2083179C (enExample)
CY (1) CY2123B1 (enExample)
CZ (4) CZ290474B6 (enExample)
DE (1) DE59010701D1 (enExample)
DK (1) DK0527736T3 (enExample)
ES (1) ES2102367T3 (enExample)
FI (1) FI105683B (enExample)
GR (1) GR3023638T3 (enExample)
HU (1) HU222234B1 (enExample)
IE (1) IE911694A1 (enExample)
IL (1) IL98163A (enExample)
LV (1) LV10575B (enExample)
NO (1) NO180118C (enExample)
NZ (1) NZ238165A (enExample)
PT (1) PT97689B (enExample)
RU (2) RU2142937C1 (enExample)
SK (3) SK281316B6 (enExample)
TW (2) TW205004B (enExample)
WO (1) WO1991017748A1 (enExample)
YU (1) YU48765B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2198655C2 (ru) * 1996-03-20 2003-02-20 Авентис Фарма Дойчланд Гмбх Комбинированный препарат, содержащий 4-(трифторметил)анилид 5-метилизоксазол-4-карбоновой кислоты и n-(4-трифторметилфенил)амид 2-циано-3-гидроксикротоновой кислоты
RU2280464C2 (ru) * 2004-03-22 2006-07-27 Александр Иванович Петенко Способ получения сухого пробиотического препарата "бацелл"
RU2722316C2 (ru) * 2015-06-17 2020-05-29 Биокон Лимитед Новый способ получения терифлуномида

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) * 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
DE59407415D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 8
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
TW314467B (enExample) 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
GB9520092D0 (en) * 1995-10-02 1995-12-06 Hoechst Roussel Ltd Chemical compounds
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
ES2257756T3 (es) * 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
EP1012150A4 (en) * 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
BR9813938A (pt) * 1997-11-04 2000-09-26 Pfizer Prod Inc Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4
MXPA00010150A (es) * 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
PL356243A1 (en) * 1999-12-16 2004-06-28 Teva Pharmaceuticals Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
DE60110043T2 (de) * 2000-02-15 2006-03-02 Teva Pharmaceutical Industries Ltd. Methode zur synthetisierung von leflunomid
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
CA2479928A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
WO2004035571A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CA2570780C (en) 2004-06-17 2013-12-03 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
AU2008247102B2 (en) * 2007-05-03 2011-11-24 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
WO2010115736A2 (en) 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
EP2451773A2 (en) 2009-07-09 2012-05-16 Alembic Pharmaceuticals Limited Novel polymorphic form of teriflunomide salts
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ レフルノミドおよびマロノニトリラマイドの新規の使用
CA2814371C (en) 2010-10-29 2019-03-19 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
WO2012110911A1 (en) 2011-02-18 2012-08-23 Alembic Pharmaceuticals Limited Novel polymorphic form of teriflunomide
EP2685983B1 (en) 2011-03-17 2016-05-18 Algiax Pharmaceuticals GmbH Novel use of imidazotriazinones
US20140057978A1 (en) 2011-03-17 2014-02-27 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
WO2015029063A2 (en) * 2013-08-30 2015-03-05 Msn Laboratories Private Limited Novel polymorph of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethyl phenyl)-amide and process for the preparation thereof
JP2016537360A (ja) 2013-11-22 2016-12-01 ジェンザイム・コーポレーション 神経変性疾患を治療するための新規な方法
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
US20170152263A1 (en) * 2014-06-20 2017-06-01 Aurigene Discovery Technologies Limited Substituted Indazole Compounds as IRAK4 Inhibitors
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
BR112019017567A2 (pt) 2017-02-24 2020-03-24 Merck Patent Gmbh Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
WO2018178947A2 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
EP3915557A1 (en) 2017-04-24 2021-12-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
MY203827A (en) 2017-10-31 2024-07-19 Curis Inc Compounds and compositions for treating hematological disorders
TR202022336A2 (tr) 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
AU2022254933A1 (en) 2021-04-08 2023-11-09 Curis, Inc. Combination therapies for the treatment of cancer
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
CN117126078B (zh) * 2022-05-19 2025-11-25 四川大学 一类化合物及在治疗hDHODH介导的疾病中的用途
EP4382097A1 (en) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising teriflunomide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2557003A1 (de) * 1975-12-18 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3405727A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. Патент США N 4087535, кл. C 07 D 261/18, 1978. 2. Патент ФРГ N 2854439, кл. C 07 D 261/18, 1980. 3. Патент ФРГ N 2524959, кл. C 07 C 121/417, 1976. 4. Патент ЕПВ N 0257882, кл. C 07 C 121/417, 1988. 5. Патент ФРГ N 3405727, кл. C 07 D 413/06, 1985. 6. Патент Канады N 1102341, кл. C 07 D 261/18, 1977. 7. Патент Великобритании N 2143732, кл. A 61 K 31/41, 1985. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2198655C2 (ru) * 1996-03-20 2003-02-20 Авентис Фарма Дойчланд Гмбх Комбинированный препарат, содержащий 4-(трифторметил)анилид 5-метилизоксазол-4-карбоновой кислоты и n-(4-трифторметилфенил)амид 2-циано-3-гидроксикротоновой кислоты
RU2280464C2 (ru) * 2004-03-22 2006-07-27 Александр Иванович Петенко Способ получения сухого пробиотического препарата "бацелл"
RU2722316C2 (ru) * 2015-06-17 2020-05-29 Биокон Лимитед Новый способ получения терифлуномида

Also Published As

Publication number Publication date
CY2123B1 (en) 2002-06-21
SK281317B6 (sk) 2001-02-12
JPH11343285A (ja) 1999-12-14
PT97689B (pt) 1998-09-30
NO924433L (no) 1992-11-17
ATE151633T1 (de) 1997-05-15
GR3023638T3 (en) 1997-08-29
NO180118B (no) 1996-11-11
TW211558B (enExample) 1993-08-21
HU222234B1 (hu) 2003-05-28
NO180118C (no) 1997-02-19
LV10575A (lv) 1995-04-20
NO924433D0 (no) 1992-11-17
TW205004B (enExample) 1993-05-01
FI105683B (fi) 2000-09-29
LV10575B (en) 1996-04-20
DK0527736T3 (da) 1997-10-20
CS145091A3 (en) 1992-01-15
JP2995086B2 (ja) 1999-12-27
EP0527736A1 (de) 1993-02-24
CZ290736B6 (cs) 2002-10-16
CZ290737B6 (cs) 2002-10-16
CZ290717B6 (cs) 2002-10-16
SK281316B6 (sk) 2001-02-12
NZ238165A (en) 1994-08-26
PT97689A (pt) 1992-02-28
FI925211A0 (fi) 1992-11-17
IL98163A (en) 1996-01-31
HU9203619D0 (en) 1993-03-29
ES2102367T3 (es) 1997-08-01
FI925211L (fi) 1992-11-17
YU88491A (sh) 1995-03-27
HUT64314A (en) 1993-12-28
CN1051074C (zh) 2000-04-05
AU649421B2 (en) 1994-05-26
BR9008022A (pt) 1993-04-06
JPH11322700A (ja) 1999-11-24
AU6546890A (en) 1991-12-10
WO1991017748A1 (de) 1991-11-28
JPH05506425A (ja) 1993-09-22
AU5799294A (en) 1994-07-07
RU94033835A (ru) 1996-04-20
EP0527736B1 (de) 1997-04-16
DE59010701D1 (de) 1997-05-22
YU48765B (sh) 1999-11-22
US5532259A (en) 1996-07-02
US5494911A (en) 1996-02-27
SK281318B6 (sk) 2001-02-12
CA2083179A1 (en) 1991-11-19
RU2142937C1 (ru) 1999-12-20
AU662465B2 (en) 1995-08-31
CZ290474B6 (cs) 2002-07-17
CN1056684A (zh) 1991-12-04
JP3201747B2 (ja) 2001-08-27
IL98163A0 (en) 1992-06-21
KR100188801B1 (ko) 1999-06-01
JP3233610B2 (ja) 2001-11-26
IE911694A1 (en) 1991-11-20
CA2083179C (en) 2001-10-23

Similar Documents

Publication Publication Date Title
RU2084223C1 (ru) Применение амидов изоказол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты
US5041653A (en) Substituted benzamide radiosensitizers
US5032617A (en) Substituted benzamide radiosensitizers
AU2019320922B2 (en) Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof
RU95116245A (ru) Производные пиримидина, способ их получения, фармкомпозиция
US5576316A (en) Method for inhibiting tumor growth rate using creatine or creatine analogs
NO333230B1 (no) Taxol-forsterkende forbindelser, farmasoytiske preparater omfattende slike samt slike forbindelser i kombinasjon med paclitaxel eller en paclitaxelanalog for behandling av kreft
JP2022121599A (ja) 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
CA2728769A1 (en) Nitrogen heterocycle derivatives as proteasome modulators
JPH08508045A (ja) 癌性疾患の予防および治療のための製剤組成物、ならびにその製造法
JPH11501024A (ja) ２−アリルベンゾアゾール化合物
WO1989007441A1 (en) 6-amino-1,2-benzopyrone antitumorigenic agents and method
US20240226096A1 (en) Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain
US6037357A (en) N-benzoyl-α-alkylated azatyrosines as anticancer agents
CA1267604A (en) Method for treating neoplastic disease
CN106822129B (zh) 苦豆碱衍生物在制备治疗肿瘤的药物中的应用
JPH01258665A (ja) 耐腫瘍活性を有する新規な１−アルキル−１−スルホニル−２−アルコキシカルボニルスルフェニルヒドラジン
US3382275A (en) Derivatives of glyoxal dithiosemicarbazone
CN114075123A (zh) 苄胺类衍生物及其制备方法与用途
US3886279A (en) Anti-inflammatory analgesic method of treatment and composition
JPH02304058A (ja) キサントシリンｘモノメチルエーテル誘導体及びそれを含有する抗腫瘍剤
FI105680B (fi) Menetelmä terapeuttisesti käyttökelpoisten hydroksialkylideenisyaanietikkahappoamidien valmistamiseksi
US5817680A (en) Hemoregulatory compounds
WO2020081852A1 (en) Selective ship inhibitors for treating disease
JPH01305029A (ja) テトラゾール誘導体の使用